NCT05101070 2026-03-18
aCCeleR8-001
Shionogi Inc.
Phase 1/2 Recruiting
Clinical Trials
15 trialsNCT05203172 2026-03-18
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Pfizer
Phase 4 Recruiting
NCT05155332 2026-03-17
A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
Phase 1 Recruiting
NCT06892379 2026-03-13
A Study of HS-20110 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07018622 2026-03-11
DAPA-ARMOR
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2 Recruiting
NCT04589845 2026-03-06
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Hoffmann-La Roche
Phase 2 Recruiting
NCT07030959 2026-02-25
Study of AUBE00 in Patients With Solid Tumors
Chugai Pharmaceutical
Phase 1 Recruiting
NCT07181681 2026-02-23
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06651593 2026-02-17
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07123103 2026-02-17
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
Exelixis
Phase 1 Recruiting
NCT06885281 2026-02-13
A Study of ZL-1310 in Participants With Selected Solid Tumors
Zai Lab (Hong Kong), Ltd.
Phase 1/2 Recruiting
NCT07351903 2026-01-20
GUARDIAN-02
Tianjin Medical University Cancer Institute and Hospital
Phase 1 Recruiting
NCT07312903 2026-01-12
DPTX3186 in Wnt Pathway Activated Solid Tumors
Dewpoint Therapeutics
Phase 1 Recruiting
NCT07265622 2025-12-29
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Recruiting
NCT06227377 2025-12-24
QTX3034 in Patients With KRAS G12D Mutation
Quanta Therapeutics
Phase 1 Recruiting